08:00 , Feb 27, 2012 |  BioCentury  |  Emerging Company Profile

Ember Therapeutics: Burning obesity

Ember Therapeutics Inc. is taking two therapeutic approaches to obesity and diabetes, one that is based on novel biology and another it thinks will improve on marketed PPAR gamma agonists. The company hopes to advance...
08:00 , Dec 19, 2011 |  BioCentury  |  Finance

Stoking the embers

Stoking the embers Ember Therapeutics officially launched last week with a $34 million series A round from Third Rock Ventures to develop a pair of preclinical projects plucked from academia that could result in peripherally...
02:35 , Dec 16, 2011 |  BC Extra  |  Financial News

Ember ignites with $34M in series A

Metabolic company Ember Therapeutics (Boston, Mass.) raised $34 million in a series A round from Third Rock Ventures. Ember (formerly Adipothermics Inc. ) is developing molecules that block the phosphorylation of peroxisome proliferation activated receptor...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Nuclear receptor corepressor 1 (NCOR1); peroxisome proliferation-activated receptor-g (PPARG; PPARg) Studies in mice suggest inhibiting interactions between NCOR1 and PPARg could help treat...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Clinical News

Adipothermics, Inc. preclinical data

Researchers at Scripps Florida and the Dana-Farber Cancer Institute reported that a non-agonist PPAR gamma targeted compound significantly improve insulin sensitivity vs. vehicle-treated controls in mouse models of Type II diabetes. Additionally, the compound reduced...
07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes Peroxisome proliferation-activated receptor-g (PPARG; PPARg); cyclin dependent kinase 5 (CDK5) In vitro and mouse studies identified PPARg-binding compounds that could help treat type 2...
07:00 , Sep 8, 2011 |  BC Innovations  |  Cover Story

PPARgamma: none is more

A team from Scripps Florida and the Dana-Farber Cancer Institute has developed peroxisome proliferation-activated receptor-g-binding compounds that have potent antidiabetic activity but do not actually agonize the receptor and thus lack the side effects commonly...